TDIQ

TDIQ
Clinical data
Other names	6,7-Methylenedioxy-1,2,3,4-tetrahydroisoquinoline; 6,7-Methylenedioxy-THIQ; MDTHIQ; MDA-CR; "MDA-Conformationally Restricted"; MDA-THIQ; MDA/THIQ
Identifiers
	IUPAC name 5,6,7,8-Tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline;
CAS Number	15052-05-8 ;
PubChem CID	27013;
ChemSpider	25154;
UNII	N2NE2TM9ZF;
CompTox Dashboard (EPA)	DTXSID00933985 ;
Chemical and physical data
Formula	C10H11NO2
Molar mass	177.203 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c23OCOc2cc1CCNCc1c3;
	InChI InChI=1S/C10H11NO2/c1-2-11-5-8-4-10-9(3-7(1)8)12-6-13-10/h3-4,11H,1-2,5-6H2; Key:JHLDJOBIUVJSTG-UHFFFAOYSA-N;
	(verify)

TDIQ, also known as MDTHIQ or MDA-CR, is a tetrahydroisoquinoline drug used in scientific research, which has anxiolytic and anorectic effects in animals.^[1]^[2] It has an unusual effects profile in animals, with the effects generalising to cocaine and partially to MDMA and ephedrine,^[3] but the effects did not generalise to amphetamine and TDIQ does not have any stimulant effects.^[4] It is thought these effects are mediated via a partial agonist action at α₂-adrenergic receptors, and TDIQ has been suggested as a possible drug for the treatment of cocaine dependence.^[5]

References

^ Young R, Rothman RB, Rangisetty JB, Partilla JS, Dukat M, Glennon RA (May 2006). "TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline) inhibits the consumption of "snacks" in mice". Pharmacology Biochemistry and Behavior. 84 (1): 74–83. doi:10.1016/j.pbb.2006.04.007. PMID 16750261. S2CID 22564648.
^ Young R, Batkai S, Dukat M, Glennon RA (May 2006). "TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline) exhibits anxiolytic-like activity in a marble-burying assay in mice". Pharmacology Biochemistry and Behavior. 84 (1): 62–73. doi:10.1016/j.pbb.2006.04.006. PMID 16750844. S2CID 12307882.
^ Young R, Glennon RA (2002). "The stimulus effect of 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline is similar to that of cocaine but different from that of amphetamine". Pharmacology Biochemistry and Behavior. 71 (1–2): 205–13. CiteSeerX 10.1.1.670.8659. doi:10.1016/S0091-3057(01)00666-9. PMID 11812524. S2CID 16553365.
^ Glennon RA, Young R, Rangisetty JB (May 2002). "Further characterization of the stimulus properties of 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline". Pharmacology Biochemistry and Behavior. 72 (1–2): 379–87. doi:10.1016/S0091-3057(01)00768-7. PMID 11900809. S2CID 33311107.
^ Young R (2007). "TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo [4,5-g]isoquinoline): discovery, pharmacological effects, and therapeutic potential". CNS Drug Reviews. 13 (4): 405–22. doi:10.1111/j.1527-3458.2007.00022.x. PMC 6494129. PMID 18078426.

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.